Unicycive Therapeutics, Inc. financial data

Symbol
UNCY on Nasdaq
Industry
Pharmaceutical Preparations
Location
4300 El Camino Real, Suite 210, Los Altos, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 211 % +69.6%
Quick Ratio 25.1 %
Debt-to-equity -1.96K % -925%
Return On Equity 3.65K % +942%
Return On Assets -87.8 % +39.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares +244%
Common Stock, Shares, Outstanding 114M shares +228%
Entity Public Float 18.7M USD -4.22%
Common Stock, Value, Issued 114K USD +226%
Weighted Average Number of Shares Outstanding, Basic 67M shares +173%
Weighted Average Number of Shares Outstanding, Diluted 67M shares +173%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 675K USD
Research and Development Expense 20M USD +55.1%
General and Administrative Expense 12.1M USD +41.6%
Operating Income (Loss) -32.1M USD -54.6%
Nonoperating Income (Expense) 2.16M USD +34.3%
Net Income (Loss) Attributable to Parent -36.7M USD -20.2%
Earnings Per Share, Basic -0.56 USD/shares +56.3%
Earnings Per Share, Diluted -0.56 USD/shares +56.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.3M USD +105%
Inventory, Net 3.11M USD +56.6%
Assets, Current 30.9M USD +131%
Property, Plant and Equipment, Net 75K USD +188%
Operating Lease, Right-of-Use Asset 645K USD -15.8%
Assets 31.7M USD +123%
Accounts Payable, Current 1.06M USD +26.1%
Accrued Liabilities, Current 3.56M USD +10.1%
Liabilities, Current 24.1M USD +37.6%
Operating Lease, Liability, Noncurrent 117K USD -74.9%
Liabilities 24.2M USD +34.7%
Retained Earnings (Accumulated Deficit) -101M USD -56.9%
Stockholders' Equity Attributable to Parent 7.43M USD
Liabilities and Equity 31.7M USD +123%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.46M USD -64.7%
Net Cash Provided by (Used in) Financing Activities 45.7M USD +64.4%
Net Cash Provided by (Used in) Investing Activities -6K USD
Common Stock, Shares Authorized 400M shares +100%
Common Stock, Shares, Issued 114M shares +228%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.1M USD +169%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5M USD
Deferred Tax Assets, Valuation Allowance 19.7M USD +76%
Deferred Tax Assets, Gross 19.8M USD +75%
Operating Lease, Liability 681K USD -14.1%
Depreciation 9K USD +350%
Payments to Acquire Property, Plant, and Equipment 6K USD
Lessee, Operating Lease, Liability, to be Paid 726K USD -18.2%
Property, Plant and Equipment, Gross 114K USD +171%
Operating Lease, Liability, Current 564K USD +72.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 118K USD -72.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 608K USD +55.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 45K USD -52.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 72K USD
Deferred Tax Assets, Operating Loss Carryforwards 11M USD +84.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.9M shares +32708%
Unrecognized Tax Benefits 1.99M USD +93.3%
Additional Paid in Capital 109M USD +78.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 169K USD +4.97%
Share-based Payment Arrangement, Expense 2.35M USD +33%
Interest Expense 90K USD +66.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%